Prognostic value of combined analysis of estrogen receptor status and cellular proliferative activity in breast cancer patients with extensive lymph node metastases

Oncology Reports

Volumn 9, Issue 3, 2002, Pages 589-594

  Takashima, Tsutomu ^a   Onoda, Naoyoshi ^a   Ishikawa, Tetsuro ^a   Ogawa, Yoshinari ^a   Kato, Yasuyuki ^a   Fujimoto, Yasuhisa ^b   Sowa, Michio ^b   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Breast cancer; Estrogen receptor; Proliferating cell nuclear antigen

Indexed keywords

ESTROGEN RECEPTOR;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL DIVISION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TIME;

BREAST NEOPLASMS; CELL DIVISION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0036583233     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.3.589     Document Type: Article

References (38)

1. Nemoto T, Vana J, Bedwani R-N, Baker H-W, McGregor F-H and Murphy G-P: Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45: 2917-2924, 1980. (Pubitemid 11191732)
2. Clark GM and McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15 (Suppl. 1): 20-25, 1988.
3. Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C and Brunet M: Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients. Eur J Cancer Clin Oncol 25: 1233-1240, 1989. (Pubitemid 19209620)
4. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52: 1551-1557, 1983. (Pubitemid 13018271)
5. Kohail HM, Elias EG, el-Nowiem SA, Bashirelahi N, Didolkar MS and Reed WP: A multifactorial analysis of steroid hormone receptors in stages I and II breast cancer. Ann Surg 201: 611-617, 1985. (Pubitemid 15014775)
6. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942, 1998.
7. Matsumoto K: Progesterone and estrogen receptor in Japanese breast cancer. In: Hormones, Receptors and Breast Cancer. McGuire WL (ed). Raven Press, New York, pp43-58, 1978.
8. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993. (Pubitemid 23289454)
9. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ and Lowe SW: bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 94: 2345-2349, 1997. (Pubitemid 27136877)
10. Celis JE, Bravo R, Larsen PM and Fey SJ: Cyclin: a nuclear protein whose level correlates directly with the proliferative state of normal as well as transformed cells. Leuk Res 8: 143-157, 1984 (Pubitemid 14149192)
11. Takasaki Y, Deng JS and Tan EM: A nuclear antigen associated with cell proliferation and blast transformation. J Exp Med 154: 1899-1909, 1981.
12. Mathews MB, Bernstein RM, Franza BR Jr and Garrels JI: Identity of the proliferating cell nuclear antigen and cyclin. Nature 309: 374-376, 1984. (Pubitemid 14145846)
13. Maeda K, Chung YS, Onoda N, Kato Y, Nitta A, Arimoto Y, et al: Proliferative cell nuclear antigen labeling index of preoperative biopsy specimens in gastric carcinoma with special reference to prognosis. Cancer 73: 528-533, 1994. (Pubitemid 24046589)
14. Horiguchi J, Iino Y, Takei H, Maemura M, Takeyoshi I, Yokoe T, et al: Long-term prognostic value of PCNA labeling index in primary operable breast cancer. Oncol Rep 5: 641-644, 1998. (Pubitemid 28189319)
15. Biesterfeld S, Kluppel D, Koch R, Schneider S, Steinhagen G. Mihalcea AM, et al: Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR. J Pathol 185:25-31, 1998. (Pubitemid 28266713)
16. Magno WB, Hirschfield L, Bhuiya T, Harrison G and Mir R: Correlation of proliferative index (PCNA reactivity and Ki-67 reactivity) in primary breast carcinoma with hormone status, lymph node status, and disease-free survival. Conn Med 56: 667-669, 1992.
17. Takashima T, Onoda N, Ishikawa T, Ogawa Y, Kato Y, Fujimoto Y, Sowa M, Hirakawa K and Chung YS: Proliferating cell nuclear antigen labeling index and p53 expression predict out come for breast cancer patients with four or more lymph node metastases. Int J Mol Med 8: 159-163, 2001.
18. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, et al: A clinicopathological study on overexpression of cyclin Dl and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73: 728-734, 1996. (Pubitemid 26105298)
19. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, et al: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965-970, 1993. (Pubitemid 23177582)
20. Niewiadomska H, Jeziorski A and Olborski B: The expression of the proliferating antigen Ki67, PCNA and products of suppressor gene p53 in primary invasive ductal breast carcinoma. J Exp Clin Cancer Res 17:503-510, 1998. (Pubitemid 29083427)
21. Aitken SC and Lippman ME: Effect of estrogens and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res 45: 1611-1620, 1985. (Pubitemid 15079113)
22. Dickson RB, Thompson EW and Lippman ME: Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. J Steroid Biochem Mol Biol 37: 305-316, 1990.
23. Stewart AJ, Johnson MD, May FE and Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265: 21172-21178, 1990. (Pubitemid 120014136)
24. MacGregor JI and Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50: 151-196, 1998.
25. Mclnerney JM, Wilson MA, Strand KJ and Chrysogelos SA: A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells. J Cell Biochem 80: 538-549, 2001. (Pubitemid 32127469)
26. Liu G, Schwartz JA and Brooks SC: Estrogen receptor protects p53 from deactivation by human double minutes-2. Cancer Res 60: 1810-1814,2000. (Pubitemid 30207635)
27. Yu CL, Driggers P, Barrera HG, Nunez SB, Segars JH and Cheng S: The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem Biophys Res Commun 239: 617-620, 1997. (Pubitemid 27489014)
28. Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Saji S and Hayashi S: MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun 281: 259-265, 2001. (Pubitemid 32924428)
29. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
30. Finlay CA, Hinds PW and Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989. (Pubitemid 19169804)
31. Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B: A model for p53-induced apoptosis. Nature 389: 300-305, 1997. (Pubitemid 27406646)
32. Kaserer K, Schmaus J, Bethge U, Migschitz B, Fasching S, Walch A, Herbst F, Teleky B and Wrba F: Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol 190: 450-456, 2000. (Pubitemid 30163585)
33. Takahashi M, Tonoki H, Tada M, Kashiwazaki H, Furuuchi K, Hamada J, Fujioka Y, Sato Y, Takahashi H, Todo S, Sakuragi N and Moriuchi T: Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 89: 92-99, 2000. (Pubitemid 30078756)
34. Chen QR and Mixson AJ: Systemic gene therapy with p53 inhibits breast cancer: recent advances and therapeutic implications. Front Biosci 3: D997-D1004, 1998.
35. Shibata MA, Yoshidome K, Shibata E, Jorcyk CL and Green JE: Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 8: 23-35, 2001. (Pubitemid 32151894)
36. Sakamoto G and Mitsuyama S: New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody. Breast Cancer 7: 350-357, 2000.
37. Mitchell MS and Press MF: The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 26 (Suppl. 12): 108-116,1999. (Pubitemid 29411441)
38. Berry DA, Muss HB, Thor AD, Dressier L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D and Norton L: HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18: 3471-3479,2000.